• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas.

出版信息

Gastroenterol Hepatol (N Y). 2013 Jan;9(1 Suppl 1):1-20.

PMID:24847183
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4027897/
Abstract
摘要

相似文献

1
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From AASLD 2012: The 63rd Annual Meeting of the American Association for the Study of Liver DiseasesNovember 9-13, 2012 • Boston, MassachusettsSpecial Reporting on:• Timing and Magnitude of Ribavirin Dose Reduction Do Not Impact SVR Rates with Boceprevir Plus Peginterferon α and Ribavirin• A 12-Week Interferon-Free Treatment Regimen with ABT-450/r, ABT-267, ABT-333, and Ribavirin Achieves High SVR12 Rates• High Rate of SVR with the All-Oral Combination of Daclatasvir Plus Sofosbuvir with or without Ribavirin• An Interferon-Free, Ribavirin-Free 12-Week Regimen of Daclatasvir, Asunaprevir, and BMS-791325 Achieved High SVR4 RatesPLUS Meeting Abstract Summaries With Expert Commentary by: Fred Poordad, MDUniversity of San Antonio Health Science CenterSan Antonio, Texas.一期特别会议回顾版：2012年美国肝病研究学会（AASLD）第63届年会丙型肝炎病毒感染治疗进展2012年11月9日至13日•马萨诸塞州波士顿特别报道：• 利巴韦林剂量减少的时间和幅度不影响波西普韦联合聚乙二醇干扰素α及利巴韦林的持续病毒学应答率（SVR）• 采用ABT - 450/r、ABT - 267、ABT - 333和利巴韦林的12周无干扰素治疗方案可实现高SVR12率• 达卡他韦联合索磷布韦加或不加利巴韦林的全口服联合方案具有高SVR率• 达卡他韦、阿舒瑞韦和BMS - 791325的无干扰素、无利巴韦林12周方案实现了高SVR4率另附会议摘要及专家评论作者：医学博士弗雷德·普尔达德德克萨斯大学圣安东尼奥健康科学中心德克萨斯州圣安东尼奥
Gastroenterol Hepatol (N Y). 2013 Jan;9(1 Suppl 1):1-20.
2
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2014: The 49th Annual Meeting of the European Association for the Study of the Liver • April 9-13, 2014 • London, United KingdomSpecial Reporting on:• SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/R/ABT-267, ABT-333, and Ribavirin in Treatment-Experienced Adults With Hepatitis C Virus Genotype 1• All Oral Fixed-Dose Combination Sofosbuvir/Ledipasvir With or Without Ribavirin for 12 or 24 Weeks in Treatment-Naive Genotype 1 HCV-Infected Patients: the Phase 3 ION-1 Study• PEARL-III: 12 Weeks of ABT-450/R/267 + ABT-333 Achieved SVR in >99% of 419 Treatment-Naive HCV Genotype 1B-Infected Adults With or Without Ribavirin• Results of the Phase 2 Study M12-999: Interferon-Free Regimen of ABT-450/R/ABT-267 + ABT-333 + Ribavirin in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection• Sofosbuvir and Ribavirin for the Treatment of Chronic HCV With Cirrhosis and Portal Hypertension With and Without Decompensation: Early Virologic Response and Safety• All-Oral Dual Therapy With Daclatasvir and Asunaprevir in Patients With HCV Genotype 1B Infection: Phase 3 Study Results• Sofosbuvir/Ledipasvir Fixed Dose Combination Is Safe and Effective in Difficult-to-Treat Populations Including Genotype-3 Patients, Decompensated Genotype-1 Patients, and Genotype-1 Patients With Prior Sofosbuvir Treatment Experience• Sofosbuvir and Ribavirin for the Treatment of Recurrent Hepatitis C Infection After Liver Transplantation: Results of a Prospective, Multicenter StudyPLUS Meeting Abstract Summaries With Expert Commentary by: Steven L. Flamm, MDChief, Liver Transplantation ProgramProfessor of Medicine and SurgeryNorthwestern University Feinberg School of MedicineChicago, Illinois.特别会议回顾版：2014年欧洲肝脏研究协会第49届年会——丙型肝炎病毒感染治疗进展•2014年4月9日至13日•英国伦敦 特别报道： • SAPPHIRE II：ABT - 450/R/ABT - 267、ABT - 333与利巴韦林组成的不含干扰素的12周方案用于治疗经验丰富的丙型肝炎病毒1型感染成人的3期安慰剂对照研究 • 索磷布韦/来迪帕司韦全口服固定剂量联合用药（含或不含利巴韦林）治疗初治1型丙型肝炎病毒感染患者12周或24周：3期ION - 1研究 • PEARL - III：ABT - 450/R/267 + ABT - 333治疗12周使419例初治丙型肝炎病毒1b型感染成人（无论是否使用利巴韦林）的持续病毒学应答率超过99% • 2期研究M12 - 999结果：ABT - 450/R/ABT - 267 + ABT - 333 + 利巴韦林不含干扰素方案用于肝移植受者复发性丙型肝炎病毒1型感染 • 索磷布韦和利巴韦林治疗伴或不伴失代偿的肝硬化和门静脉高压的慢性丙型肝炎：早期病毒学应答和安全性 • 达卡他韦和阿舒瑞韦全口服双联疗法治疗丙型肝炎病毒1b型感染患者：3期研究结果 • 索磷布韦/来迪帕司韦固定剂量联合用药在包括3型患者、失代偿1型患者和有索磷布韦治疗史的1型患者等难治人群中安全有效 • 索磷布韦和利巴韦林治疗肝移植后复发性丙型肝炎感染：一项前瞻性多中心研究结果 加会议摘要总结及专家评论： 医学博士史蒂文·L·弗拉姆（Steven L. Flamm） 西北大学费恩伯格医学院肝脏移植项目主任 医学与外科学教授 伊利诺伊州芝加哥市
Gastroenterol Hepatol (N Y). 2014 Jun;10(6 Suppl 2):1-19.
3
A SPECIAL MEETING REVIEW EDITION: Highlights in the Treatment of Hepatitis C Virus From the 2014 Liver Meeting: A Review of Selected Presentations From the 2014 Liver Meeting November 7-11, 2014 • Boston, MassachusettsSpecial Reporting on:• Evaluation of Sofosbuvir and Simeprevir-Based Regimens in the TRIO Network• Safety and Efficacy of New DAA-Based Therapy for Hepatitis C Post-Transplant: Interval Results From the HCV-TARGET Longitudinal, Observational Study• Efficacy and Safety of MK-5172 and MK-8742 ± Ribavirin in Hepatitis C Genotype 1 Infected Patients With Cirrhosis or Previous Null Response: Final Results of the C-WORTHY Study (Parts A & B)• Safety and Efficacy of Sofosbuvir in Combination With Simeprevir + Ribavirin in Patients With Genotype 1: Interim Results of a Prospective, Observational Study• All-Oral Fixed-Dose Combination Therapy With Daclatasvir/Asunaprevir/BMS-791325, ± Ribavirin, for Patients With Chronic HCV Genotype 1 Infection and Compensated Cirrhosis: UNITY-2 Phase 3 SVR-12 Results• TURQUOISE-II: Regimens of ABT-450/R/Ombitasvir and Dasabuvir With Ribavirin Achieve High SVR12 Rates in HCV Genotype 1-Infected Patients With Cirrhosis, Regardless of Baseline CharacteristicsPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDChief of the Division of Gastroenterology and HepatologyVincent Astor Distinguished Professor of MedicineWeill Cornell Medical CollegeAttending PhysicianNewYork-Presbyterian HospitalNew York, New York.特别会议回顾版：2014年肝脏会议丙型肝炎病毒治疗亮点：2014年肝脏会议精选报告回顾，2014年11月7日至11日，马萨诸塞州波士顿。特别报道：•TRIO网络中基于索非布韦和西米普明的治疗方案评估；•基于新型直接抗病毒药物的丙型肝炎移植后治疗的安全性和有效性：HCV-TARGET纵向观察性研究的中期结果；•MK-5172和MK-8742±利巴韦林在丙型肝炎基因1型感染的肝硬化患者或既往无应答患者中的疗效和安全性：C-WORTHY研究（A和B部分）的最终结果；•索非布韦联合西米普明+利巴韦林在基因1型患者中的安全性和有效性：一项前瞻性观察性研究的中期结果；•达卡他韦/阿舒瑞韦/BMS-791325全口服固定剂量联合治疗，±利巴韦林，用于慢性丙型肝炎基因1型感染和代偿性肝硬化患者：UNITY-2 3期SVR-12结果；•TURQUOISE-II：ABT-450/R/奥比他韦和达沙布韦联合利巴韦林方案在丙型肝炎基因1型感染的肝硬化患者中实现了高SVR12率，无论基线特征如何。另外还有会议摘要及专家评论：医学博士 Ira M. Jacobson，胃肠病学和肝病科主任，威尔康奈尔医学院医学Vincent Astor杰出教授，纽约长老会医院主治医师，纽约，纽约。
Gastroenterol Hepatol (N Y). 2014 Dec;10(12 Suppl 6):1-19.
4
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection from The Liver Meeting 2013: The 64th Annual Meeting of the American Association for the Study of Liver DiseasesNovember 1-5, 2013 • Washington DCSpecial Reporting on:• Simeprevir plus Sofosbuvir with or without Ribavirin Produces High SVR Rates in Genotype 1 HCV Infection• Novel Interferon- and Ribavirin-Free Regimen Results in SVR12 Rates of Over 90% in HCV Genotype 1b Infection• Studies Confirm Efficacy of Adjunctive Simeprevir in Difficult-to-Treat HCV Genotype 1 Subpopulations• All-Oral Therapy with Sofosbuvir Plus Ribavirin Produces High SVR Rates in Patients Coinfected with HCV and HIV• Faldaprevir Combined with Pegylated Interferon and Ribavirin Demonstrates High Efficacy in DifficuIt-to-Treat HCV Infection• Once Daily Sofosbuvir/Ledipasvir Combination Elicits Rapid Decline in HCV RNAPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDWeill Cornell Medical CollegeNew York, New York.特别会议回顾版：2013年肝脏会议丙型肝炎病毒感染治疗进展：美国肝病研究协会第64届年会，2013年11月1日至5日，华盛顿特区。特别报道：• 西米普明联合索非布韦，加或不加利巴韦林，在基因1型丙型肝炎病毒感染中产生高持续病毒学应答率；• 新型无干扰素和利巴韦林方案在丙型肝炎病毒基因1b型感染中导致超过90%的12周持续病毒学应答率；• 研究证实辅助性西米普明在难治性丙型肝炎病毒基因1型亚群中的疗效；• 索非布韦联合利巴韦林的全口服疗法在丙型肝炎病毒和人类免疫缺陷病毒合并感染患者中产生高持续病毒学应答率；• 法达普明联合聚乙二醇干扰素和利巴韦林在难治性丙型肝炎病毒感染中显示出高疗效；• 每日一次索非布韦/雷迪帕韦组合使丙型肝炎病毒RNA迅速下降。 PLUS会议摘要及专家评论，作者：医学博士艾拉·M·雅各布森，威尔康奈尔医学院，纽约，纽约。
Gastroenterol Hepatol (N Y). 2014 Jan;10(1 Suppl 1):1-19.
5
A SPECIAL MEETING REVIEW EDITION: Advances in the Treatment of Hepatitis C Virus Infection From EASL 2013: The 48th Annual Meeting of the European Association for the Study of the LiverApril 24-28, 2013 • Amsterdam, The NetherlandsSpecial Reporting on:• Simeprevir Plus Peginterferon/Ribavirin Is Associated with a High SVR12 Rate in Treatment-Naive Patients with Genotype 1 Hepatitis C Virus Infection• Addition of Simeprevir to Peginterferon/Ribavirin Is Associated with Faster Resolution of Fatigue in Treatment-Naive Patients• Sofosbuvir Plus Ribavirin Demonstrates Significant Efficacy in Multiple HCV Genotype 2/3 Populations• Daclatasvir Plus Sofosbuvir with or without Ribavirin Yields 100% SVR24 Rate in Genotype 1 Patients Who Fail Telaprevir or Boceprevir• Addition of TG4040 Vaccine to Peginterferon/Ribavirin Increases Sustained Virologic Response Rate at 24 Weeks in Genotype 1 Hepatitis C InfectionPLUS Meeting Abstract Summaries With Expert Commentary by: Ira M. Jacobson, MDJoan Sanford I. Weill Medical College at Cornell UniversityNew York, New York.一期特别会议回顾版：2013年欧洲肝脏研究协会（EASL）第48届年会中丙型肝炎病毒感染治疗的进展 2013年4月24 - 28日 • 荷兰阿姆斯特丹 专题报道： • 西米普明联合聚乙二醇干扰素/利巴韦林治疗初治基因1型丙型肝炎病毒感染患者的SVR12率高 • 初治患者中，在聚乙二醇干扰素/利巴韦林中添加西米普明可更快缓解疲劳 • 索磷布韦联合利巴韦林在多个丙型肝炎病毒基因2/3型人群中显示出显著疗效 • 对于替拉普韦或博赛泼维治疗失败的基因1型患者，达克拉他韦联合索磷布韦（加或不加利巴韦林）的SVR24率达100% • 在基因1型丙型肝炎感染中，在聚乙二醇干扰素/利巴韦林中添加TG4040疫苗可提高24周时的持续病毒学应答率 另附会议摘要及专家评论： 医学博士 Ira M. Jacobson 纽约州纽约市康奈尔大学琼·桑福德·I·韦尔医学院
Gastroenterol Hepatol (N Y). 2013 Jun;9(6 Suppl 3):1-18.
6
A SPECIAL MEETING REVIEW EDITION: Highlights in Hepatitis C Virus From the 2017 AASLD Liver Meeting: A Review of Selected Presentations From the 2017 AASLD Liver Meeting • October 20-24, 2017 • Washington, DC• Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis• Hepatitis C Virus Reinfection and Injecting Risk Behavior Following Elbasvir/Grazoprevir Treatment in Participants on Opiate Agonist Therapy: Co-STAR Part B• Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-Naive Patients With Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis• SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study• Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-Infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program• The C-BREEZE 1 and 2 Studies: Efficacy and Safety of Ruzasvir Plus Uprifosbuvir for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection100% SVR With 8 Weeks of Ledipasvir/Sofosbuvir in HIV-Infected Men With Acute HCV Infection: Results From the SWIFT-C Trial (Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-Infected Individuals)Chief, HepatologyUniversity Transplant CenterClinical Professor of MedicineThe University of Texas Health, San AntonioSan Antonio, Texas.一期特别会议回顾版：2017年美国肝病研究学会肝脏会议丙肝病毒研究亮点：2017年美国肝病研究学会肝脏会议部分报告回顾 • 2017年10月20 - 24日 • 华盛顿特区• 格卡瑞韦/哌柏瑞韦治疗慢性1 - 6型丙肝病毒感染合并代偿期肝硬化成人患者的疗效、安全性及药代动力学：一项综合分析• 接受阿片类激动剂治疗的参与者在接受艾尔巴韦/格拉瑞韦治疗后丙肝病毒再感染及注射风险行为：CO - STAR B部分• 格卡瑞韦/哌柏瑞韦治疗初治慢性丙肝基因3型患者8周或12周的疗效与安全性：一项2/3期综合分析• NS5A抑制剂经治的丙肝病毒感染患者使用索磷布韦/维帕他韦/伏西瑞韦治疗12周：3期POLARIS - 1研究中延迟治疗组的结果• 丙肝病毒感染患者对泛基因型格卡瑞韦/哌柏瑞韦治疗的依从性及SVR12：2/3期临床试验项目的综合分析• C - BREEZE 1和2研究：鲁扎斯韦联合乌普瑞司他韦治疗慢性丙肝病毒基因1、2、3、4或6型感染成人患者12周的疗效与安全性100% SVR率，使用来迪派韦/索磷布韦治疗8周，用于感染艾滋病毒的急性丙肝男性患者：SWIFT - C试验（不含干扰素的含索磷布韦方案治疗艾滋病毒1型感染个体的急性丙肝）结果肝病科主任大学移植中心医学临床教授德克萨斯大学健康科学中心圣安东尼奥分校德克萨斯州圣安东尼奥
Gastroenterol Hepatol (N Y). 2017 Dec;13(12 Suppl 5):1-24.
7
Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders.达卡他韦和asunaprevir 联合聚乙二醇干扰素α和利巴韦林治疗 HCV 基因型 1 或 4 无应答者。
J Hepatol. 2015 Jul;63(1):30-7. doi: 10.1016/j.jhep.2015.02.018. Epub 2015 Feb 19.
8
Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection.达卡他韦、asunaprevir 和 BMS-791325 联合无干扰素和利巴韦林方案治疗初治慢性丙型肝炎病毒 1 型感染患者的疗效。
Gastroenterology. 2014 Feb;146(2):420-9. doi: 10.1053/j.gastro.2013.10.057. Epub 2013 Oct 30.
9
A SPECIAL MEETING REVIEW EDITION: Updates in the Treatment of Hepatitis C Virus Infection From EASL 2012: The 47th Annual Meeting of the European Association for the Study of the LiverApril 18-22, 2012 • Barcelona, SpainSpecial Reporting on:• Safety of Telaprevir or Boceprevir in Combination with Peginterferon α/Ribavirin in Cirrhotic Nonresponders. First Results of the French Early Access Program (ANRS C020-CUPIC)• SVR in Prior Peginterferon/Ribavirin (PR) Treatment Failures After Re-treatment with Boceprevir + PR: The PROVIDE Study Interim Results• Futility Rules in Telaprevir Combination Treatment• Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End-of-Treatment (Week 48) Interim ResultsPLUS Meeting Abstract Summaries With Expert Commentary by: Jean-Pierre Bronowicki, MD, PhDDepartment of Hépato-GastroenterologieCentre Hospitalier Universitaire de Nancy-BraboisVandoeuvre-lès-Nancy, France.特别会议回顾版：2012年欧洲肝脏研究协会第47届年会丙型肝炎病毒感染治疗的最新进展 2012年4月18 - 22日•西班牙巴塞罗那 特别报道： • 特拉匹韦或博赛匹韦联合聚乙二醇干扰素α/利巴韦林用于肝硬化无应答者的安全性。法国早期获取项目（ANRS C020 - CUPIC）的初步结果 • 博赛匹韦 + 聚乙二醇干扰素/利巴韦林再治疗先前聚乙二醇干扰素/利巴韦林（PR）治疗失败患者后的持续病毒学应答：PROVIDE研究中期结果 • 特拉匹韦联合治疗中的无效规则 • 博赛匹韦加聚乙二醇干扰素/利巴韦林治疗HCV/HIV合并感染患者：治疗结束（第48周）中期结果 PLUS会议摘要及专家评论 作者：让 - 皮埃尔·布罗诺维茨基，医学博士、哲学博士 法国南锡大学医院中心布拉博瓦胃肠肝病科 法国南锡万多夫勒莱南锡
Gastroenterol Hepatol (N Y). 2012 Jun;8(6 Suppl 3):1-20.
10
Randomized trial of daclatasvir and asunaprevir with or without PegIFN/RBV for hepatitis C virus genotype 1 null responders.达卡他韦和asunaprevir 联合或不联合 PegIFN/RBV 治疗丙型肝炎病毒 1 型无应答者的随机试验。
J Hepatol. 2014 Mar;60(3):490-9. doi: 10.1016/j.jhep.2013.10.019. Epub 2013 Oct 26.

本文引用的文献

1
Preclinical Profile and Characterization of the Hepatitis C Virus NS3 Protease Inhibitor Asunaprevir (BMS-650032).丙型肝炎病毒 NS3 蛋白酶抑制剂asunaprevir（BMS-650032）的临床前特征和鉴定。
Antimicrob Agents Chemother. 2012 Oct;56(10):5387-96. doi: 10.1128/AAC.01186-12. Epub 2012 Aug 6.
2
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.达卡他韦治疗初治慢性丙型肝炎基因 1 型感染：一项随机、平行分组、双盲、安慰剂对照、剂量探索、2a 期临床试验。
Lancet Infect Dis. 2012 Sep;12(9):671-7. doi: 10.1016/S1473-3099(12)70138-X. Epub 2012 Jun 18.
3
Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus.PSI-7977 作为一种核苷酸抑制剂的基因型和亚型分析对丙型肝炎病毒。
Antimicrob Agents Chemother. 2012 Jun;56(6):3359-68. doi: 10.1128/AAC.00054-12. Epub 2012 Mar 19.
4
Multiple ascending dose study of BMS-790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1.BMS-790052（一种非结构蛋白 5A 复制复合物抑制剂）在感染 HCV 基因 1 型的患者中的多剂量递增研究。
Hepatology. 2011 Dec;54(6):1956-65. doi: 10.1002/hep.24609.
5
Discovery of a β-d-2'-deoxy-2'-α-fluoro-2'-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus.发现一种β-d-2'-脱氧-2'-α-氟-2'-β-C-甲基尿苷核苷酸前药（PSI-7977），用于治疗丙型肝炎病毒。
J Med Chem. 2010 Oct 14;53(19):7202-18. doi: 10.1021/jm100863x.
6
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect.化学遗传学策略鉴定出一种具有强大临床效果的 HCV NS5A 抑制剂。
Nature. 2010 May 6;465(7294):96-100. doi: 10.1038/nature08960. Epub 2010 Apr 21.